About This Project

Establish a three-layer global biosecurity oversight architecture to manage dual-use biotechnology risks while preserving the benefits of open science: (1) Mandatory Dual-Use Research Registry: All research involving enhanced pandemic pathogens, heritable human gene editing, or synthetic biology above defined capability thresholds must be registered with a WHO-administered international database before commencing. Modeled on clinical trial pre-registration — registration does not prevent research, but enables oversight. (2) Universal DNA Synthesis Screening: All commercial DNA synthesis orders above 200 base pairs screened against a regularly updated database of dangerous sequences. The technology exists and is already implemented by responsible providers — mandate it for all providers globally through export control law. (3) International Biosecurity Agency (IBA): An IAEA-equivalent body with technical inspection authority over high-risk biological facilities, a rapid-response biosecurity incident team, and the mandate to develop binding international standards for dual-use research governance. Initial capitalization of $500M, staffed by seconded national biosafety experts.

Timeline